Journal of Asthma and Allergy最新文献

{"title":"Proposal and Verification of New Revised Criteria for ABPA/ABPM Diagnosis.","authors":"Runjin Cai, Huan Ge, Bin Liu, Yuling Tang, Jun Wang, Xuemei Chen, Bing Liu, Xinyue Hu, Shuanglinzi Deng, Hui Li, Lixue Dai, Jiale Tang, Chendong Wu, Xiaoxiao Gong, Guo Wang, Xiaozhao Li, Juntao Feng","doi":"10.2147/JAA.S514664","DOIUrl":"10.2147/JAA.S514664","url":null,"abstract":"<p><strong>Background: </strong>Although several diagnostic criteria for allergic bronchopulmonary aspergillosis (ABPA) have been proposed, the disease remains frequently misdiagnosed and underdiagnosed. In 2021, Asano et al introduced new diagnostic criteria for allergic bronchopulmonary mycosis (ABPM), which were found to improve diagnostic sensitivity compared to existing criteria, but the specificity was lower.</p><p><strong>Methods: </strong>To develop revised scoring criteria for ABPA/ABPM diagnosis, delphi surveys were conducted with two rounds in 14 experts. The integer value of the mean importance scores for each item was used as the assigning values of revised scoring criteria. We evaluated the performance of existing diagnostic criteria against revised scoring criteria, using both physician diagnosis and latent class analysis (LCA) diagnosis of ABPM as reference standard.</p><p><strong>Results: </strong>We screened a total of 168 patients as initial suspected ABPM. Using physician diagnosis as the reference, diagnostic sensitivity for the Rosenberg-Patterson criteria, ISHAM criteria, revised ISHAM criteria, Asano criteria and revised scoring criteria were 39.8%, 51.6%, 64.5%, 76.3% and 86.0%, while the diagnostic specificity was 100%, 100%, 100%, 85.3% and 94.7%, respectively. When using LCA as the reference, the sensitivities of these criteria were 45.1%, 48.0%, 56.7%, 71.0%, and 76.4%, the diagnostic specificity was 100%, 100%, 98.4%, 83.8% and 95.2%, respectively.</p><p><strong>Conclusion: </strong>Revised scoring criteria showed improved diagnostic sensitivity compared to existing criteria while also enhancing specificity compared to the Asano criteria.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"467-477"},"PeriodicalIF":3.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma.","authors":"Airidas Rimkunas, Andrius Januskevicius, Egle Vasyle, Jolita Palacionyte, Virginija Kalinauskaite-Zukauske, Skaidrius Miliauskas, Kestutis Malakauskas","doi":"10.2147/JAA.S509001","DOIUrl":"10.2147/JAA.S509001","url":null,"abstract":"<p><strong>Purpose: </strong>Mepolizumab, which causes a decrease in the number of blood eosinophils, is used to treat patients with severe eosinophilic asthma (SEA). However, there is a relative lack of data on dynamic changes in blood eosinophil subtype distribution and their granule protein expression following anti-interleukin (IL)-5 treatment. Our objective was to evaluate blood inflammatory-like (iEOS-like) and resident-like (rEOS-like) eosinophil subtype distribution and <i>CLC, EDN, EPX, ECP</i>, and <i>MBP</i> gene expression following up to 24 weeks of treatment with mepolizumab in SEA patients.</p><p><strong>Patients and methods: </strong>Ten free of oral steroids SEA patients and 9 healthy control subjects (HS) were included. Patients were treated with mepolizumab 100 mg subcutaneously/4 weeks, and investigation tests were performed at 0, 4, 12, and 24 weeks. Blood eosinophils were isolated by Ficoll centrifugation and magnetic separation, then subtyped using magnetic separation against CD62L. Gene expression investigation was done using quantitative real time-polymerase chain reaction analysis.</p><p><strong>Results: </strong>Approximately three-quarters of isolated blood eosinophils were iEOS-like cells before mepolizumab treatment, p<0.01. Blood eosinophil granule protein gene expression was increased in SEA patients compared to the HS, <i>p</i><0.05, and iEOS-like cells <i>EPX, MBP</i>, and <i>CLC</i> gene expressions were higher than rEOS-like cells, <i>p</i><0.05. Following 4, 12, and 24 weeks of treatment with mepolizumab, residual blood eosinophils shifted towards rEOS-like cells, <i>p</i><0.05, and <i>CLC, EPX, ECP</i>, and <i>MBP</i> gene expression of both eosinophil subtypes decreased to HS levels.</p><p><strong>Conclusion: </strong>Treating SEA patients with mepolizumab shifts blood eosinophil subtype distribution towards rEOS-like cells and reduces granule protein gene expression levels to those of healthy individuals.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"455-466"},"PeriodicalIF":3.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11963823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access to Pediatric Asthma Specialty Care: A Survey and Geospatial Analysis Across a Rural State.","authors":"James C Bohnhoff, Dana Schwartz, Anya Cutler, Jill S Halterman","doi":"10.2147/JAA.S511581","DOIUrl":"10.2147/JAA.S511581","url":null,"abstract":"<p><strong>Objective: </strong>Although children with asthma have improved outcomes when accessing asthma specialists (allergist/immunologists and pediatric pulmonologists), this care may not be available if no specialists are located nearby, or if nearby specialists do not accept children or a given child's insurance. We aimed to describe the physical proximity of children to pediatric asthma specialty care in a largely rural state and to assess the degree to which the availability of pediatric specialty asthma care was impacted by provider nonacceptance of pediatric patients and patients with Medicaid insurance.</p><p><strong>Methods: </strong>We conducted a telephone survey of pediatric pulmonology and allergy/immunology practices in the rural state of Maine and adjacent areas during June and July 2024, asking whether they accepted pediatric patients, whether they accepted pediatric patients with Maine Medicaid insurance, and their wait times for new patient appointments. We assessed the association of acceptance policies and clinician specialty (allergy vs pulmonology), training (physician vs advanced practice provider), and state (Maine vs other) using Fisher's exact tests and we calculated the travel time to the nearest provider locations for children across Maine.</p><p><strong>Results: </strong>Among 49 asthma specialists in and around Maine, 41 (84%) accepted pediatric patients. Eighty-nine percent of Maine providers and 6% of out-of-state providers accepted children with Maine Medicaid insurance. The median distance to any asthma specialist was 30.5 minutes (IQR 17.2, 51.0) and 18% of children would need to travel >60 minutes for care.</p><p><strong>Conclusion: </strong>Nearly one in five children in Maine would be required to travel more than 60 minutes to reach an asthma specialist, nearly one in five allergy providers do not accept children, and few out of state providers accept Maine Medicaid insurance. Future research should assess the impacts of these barriers on children's receipt of care.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"447-454"},"PeriodicalIF":3.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Notch Signaling Pathway Interfering as a Possible Asthma Treatment: A Narrative Review.","authors":"Jingya Wang, Kang Yan, Leilei Ma, Xianglei Yan, Zihan Meng, Ji-An Li, Meng Wang, Chenguang Du, Yueyue Yu","doi":"10.2147/JAA.S504925","DOIUrl":"10.2147/JAA.S504925","url":null,"abstract":"<p><p>Asthma is a respiratory disease common among all age groups, and there is currently no cure that can be applied, as the patients react differently to the available treatments. Recent studies have shown that the Notch signaling pathway can regulate the dynamic balance between Th1 and Th2 cells, inhibit airway inflammation, reduce airway hyperresponsiveness and remodeling, and promote mesenchymal stem cell (MSCs) homing. This study conducted a comprehensive search of multiple large databases and provided a narrative review of the role of the Notch signaling pathway in asthma.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"437-446"},"PeriodicalIF":3.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hotspots and Trends in Allergic Rhinitis Nasal Mucosa Studies: A Bibliometric Analysis (2010-2024).","authors":"Meiya Wang, Linyou Fu, Huan Wang, Li Tian","doi":"10.2147/JAA.S503477","DOIUrl":"10.2147/JAA.S503477","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to conduct a bibliometric and visual analysis of the research on the nasal mucosa in allergic rhinitis (AR) and to explore its emerging trends, hotspots, and future development.</p><p><strong>Methods: </strong>We comprehensively searched the Web of Science Core Collection (WoSCC) for literature related to the nasal mucosa in AR published between 2010 and 2024. Bibliometric and visual analyses were performed using CiteSpace, VOSviewer, and the R language.</p><p><strong>Results: </strong>A total of 1124 relevant articles were included in this study, and the analysis showed that the number of articles in this field has been increasing year by year. China dominated the article output, followed by South Korea and Japan. American Journal of Rhinology & Allergy (69 articles) topped the list of publications; keyword analysis showed that \"immune response\", \"inflammatory response\", \"autophagy\", \"NLRP3 inflammasome\", and \"miRNAs\" are hotspots in this field.</p><p><strong>Conclusion: </strong>Over the past decade, research related to the nasal mucosa in AR have gained growing interest. This study is the first to use visualization software and data mining information to conduct a bibliometric analysis in this particular field, thereby providing fresh perspectives on the research terrain.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"417-435"},"PeriodicalIF":3.7,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Ragweed Allergy: Molecular Allergens and Integrated Control Strategies.","authors":"Zi-Lu Cheng, Ting-Ting Ma, Zhong-Shan Gao, Wen-Hua Ming, Mei-Rong Yang, Xue-Yan Wang","doi":"10.2147/JAA.S506897","DOIUrl":"10.2147/JAA.S506897","url":null,"abstract":"<p><p>Originally native to North America, ragweed has become a pervasive invasive species worldwide over the past century, posing a substantial public health risk as a potent allergen. This review explores the key allergens found in common ragweed, assesses global trends in ragweed sensitization, particularly in China, and examines various therapeutic and biological control methods. There are currently 11 identified ragweed allergens, with Amb a 1 and 11 recognized as the primary triggers. Epidemiological data indicate higher rates of sensitization in North America and Europe, with a growing trend observed in China. Ragweed-induced type I hypersensitivity typically presents as seasonal allergic rhinitis, conjunctivitis, and asthma symptoms. Strategies for managing ragweed allergy include allergen avoidance, pharmacotherapy, and allergen immunotherapy (AIT). Biological control using <i>Ophraella communa</i> and <i>Epiblema strenuana</i> effectively limits ragweed proliferation. Accurate allergen identification and personalized treatment can significantly reduce the health burden associated with ragweed. An in-depth understanding of ragweed sensitization patterns and biological control measures is essential for the long-term prevention of ragweed allergies.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"403-416"},"PeriodicalIF":3.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of Impulse Oscillometry Combined with Fractional Exhaled Nitric Oxide in Monitoring Asthma Control Levels in Children.","authors":"Jie Hu, Yinghong Fan, Ronghua Luo, Qianqian Li, Tao Ai, Li Wang","doi":"10.2147/JAA.S507446","DOIUrl":"10.2147/JAA.S507446","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate whether Impulse Oscillometry (IOS) could more effectively monitor children with uncontrolled asthma and evaluate small airway function changes, while establishing a prediction model in combination with fractional exhaled nitric oxide (FeNO) to assist in clinical management and treatment of asthmatic children.</p><p><strong>Patients and methods: </strong>A retrospective study was conducted on 203 asthmatic children who were followed up in our hospital from August 2023 to August 2024. Patients were divided into controlled asthma group (n=80) and uncontrolled asthma group (n=123). Conventional ventilatory parameters, IOS parameters, FeNO levels, and clinical data were analyzed and compared between the two groups. The optimal prediction model was established through multivariate logistic regression.</p><p><strong>Results: </strong>In the uncontrolled asthma group, the respiratory system impedance at 5 hz (Z5), resistance at 5 hz (R5), the difference between resistance at 5 hz and resistance at 20 hz (R5-R20), resonant frequency (Fres), and FeNO levels were significantly higher compared to the controlled asthma group. The ratio of forced expiratory volume in one second to forced vital capacity (FEV₁/FVC), forced expiratory flow at 50% (FEF50), forced expiratory flow at 75% (FEF75), and maximal mid-expiratory flow (MMEF) were lower in the uncontrolled group (P<0.05). Receiver operating characteristic curve (ROC) analysis demonstrated that Z5, R5, R5-R20, Fres, and FeNO were valuable in asthma diagnosis (P<0.05), with higher sensitivity in monitoring small airway function compared to MMEF. Multivariate logistic regression analysis established the optimal prediction model combining R5+(R5-R20) +FeNO, with an area under curve (AUC) of 0.915 (P<0.05), sensitivity of 0.831, and specificity of 0. 892.</p><p><strong>Conclusion: </strong>Compared to conventional pulmonary function tests, IOS effectively identifies uncontrolled status in asthmatic children, particularly in younger patients, with higher sensitivity to small airway function changes. The model comprising R5+(R5-R20) +FeNO demonstrates clinical value in identifying uncontrolled status in asthmatic children.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"391-402"},"PeriodicalIF":3.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiological Small Airways Dysfunction and the Bronchodilator Response in Adults With Asthma and Its Risk Factors: A Retrospective Analysis.","authors":"Mohammed A Almeshari, Nowaf Y Alobaidi, James A Stockley, Robert A Stockley, Prasad Nagakumar, Benjamin Paul Sutton, Elizabeth Sapey","doi":"10.2147/JAA.S489893","DOIUrl":"10.2147/JAA.S489893","url":null,"abstract":"<p><strong>Background: </strong>Physiological evidence of small airways dysfunction (SAD) is present in some patients with asthma and is associated with poor disease control. It is unclear if this represents a distinct phenotype of asthma or if it is an early manifestation of the disease. The study aimed to evaluate SAD in asthma and its clinical associations.</p><p><strong>Methods: </strong>A retrospective analysis of routinely collected health data obtained from adults referred for routine spirometric assessment as part of their clinical management. The Maximal Mid-Expiratory Flow (MMEF) z-scores were used to assess the prevalence and association factors for SAD. Pre- and post-bronchodilator data of MMEF and FEV₁ in patients with and without SAD or airflow obstruction (AO) were analysed.</p><p><strong>Results: </strong>A total of 1094 patients were included. 366 (33.5%) had evidence of SAD of whom 261 (71.3%) also had AO. Current smokers were at an increased risk of having SAD (OR: 2.05; 95% CI: 1.43-2.93). 214 patients had Bronchodilator response (BDR) data with 157 (73.4%) demonstrating BDR for MMEF and 121 (56.5%) for FEV₁. SAD at baseline was associated with a significant BDR for FEV₁ (OR of 3.59 (95% CI: 1.77-7.57)) and MMEF (OR of 2.89 (95% CI: 1.41-5.95)). Males were less likely to have a positive BDR for MMEF than females (OR of 0.46; 95% CI: 0.24-0.89).</p><p><strong>Conclusion: </strong>SAD is common in asthma and is related to the presence of AO, cigarette smoking and is associated with increased BDR for both FEV₁ and MMEF. The assessment of SAD in routine clinical practice may help identify airway impairment early for the initiation of targeted therapies.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"377-389"},"PeriodicalIF":3.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors for the Efficacy of 4-Week Dupilumab Treatment in Atopic Dermatitis Patients.","authors":"Ling Yu, Cheng Lian, Linfeng Li, JianGuo Li, Shoumin Zhang","doi":"10.2147/JAA.S508697","DOIUrl":"10.2147/JAA.S508697","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a common inflammatory disease with heterogeneous clinical features. Certain meaningful phenotypes and clinical features may help better classify AD patients for personalized medicine. To our knowledge, no ideal predictors have been found so far. We aim to investigate clinical predictors for the 4-week efficacy of dupilumab treatment in AD patients in the real world.</p><p><strong>Methods: </strong>Two hundred and thirty-three AD patients treated with dupilumab were enrolled between June 2020 and December 2023. Patients' information, characteristics, and medical history were collected. They were evaluated at the baseline and 4 weeks after dupilumab treatment and divided into groups according to the Investigator's Global Assessment (IGA) and peak pruritus numerical rating scale (PP-NRS) score. Statistical analyses were used to evaluate potential predictors.</p><p><strong>Results: </strong>Age increase, late-onset, erythroderma type, and elevation of total serum IgE level were risk factors for poor response after 4-week treatment. Female, atopic personal or family history, and allergic rhinitis were factors for better response. Multivariate logistic regression analysis showed extrinsic AD had a poor reaction than intrinsic AD (OR=4.792,95% CI 1.460-15.732, <i>p</i>=0.010), so did chronic eczema to acute-subacute eczema (OR=2.386,95% CI 1.247-4.566, <i>p</i>=0.009). Trends to decrease the risk were found for allergic rhinitis (OR=0.315,95% CI 0.202-0.967, <i>p</i>=0.001), and atopic family history (OR=0.442,95% CI 0.159-0.622, <i>p</i>=0.041).</p><p><strong>Conclusion: </strong>Extrinsic AD and chronic lichenoid eczema are risk factors for poor response to 4-week dupilumab treatment, which suggests that AD patients with extrinsic and chronic lichenoid eczema may need more patience for long-term treatment or make other options.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"331-337"},"PeriodicalIF":3.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of Protein Classes With Cross-Reactivity and Cross-Sensitization in Furry Animal Allergens: A Component-Resolved Diagnostics Study.","authors":"Jiancai Lu, Huiqing Zhu, Qingqing Yang, Yunjian Xu, Zhifeng Huang, Baoqing Sun","doi":"10.2147/JAA.S505066","DOIUrl":"10.2147/JAA.S505066","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the molecular sensitization patterns of cats, dogs, and horses in patients with cat and/or dog sensitization and the IgE cross-reactivity with other furry animals.</p><p><strong>Methods: </strong>In 95 patients diagnosed with allergic diseases and sensitized to cats and/or dogs (confirmed by specific Immunoglobulin E (sIgE) ≥ 0.35 kU_A/L to crude cat and/or dog dander extracts), sIgE levels of cat components (Fel d 1/2/4), dog components (Can f 1/2/3/5), horse dander (Equ c 1), as well as allergens from cow, guinea pig, mouse, rat, rabbit, and chicken, were measured. Sensitization profiles and cross-reactivity were analyzed. Inhibition tests using serum albumin (SA) and lipocalin proteins were performed.</p><p><strong>Results: </strong>Sensitization rates of crude extracts from other furry animals ranged from 16.8% to 49.5%. A strong positive correlation between cat and dog serum albumin (Fel d 2 and Can f 3) and rabbit epithelium, mouse epithelium, guinea pig epithelium and rat epithelium (rs: 0.66-0.87, all P < 0.05), while the lipocalin family (Fel d 4, Can f 1, Can f 2 and Equ c 1) only had a low to moderate correlation with the epithelial allergens of the above four animals (rs: 0.36-0.65, all P < 0.05). Simultaneous sensitization to SA and these four furry animal allergens accounted for 42.4%. sIgE levels of furry animal extracts were significantly higher in SA-positive groups (all P < 0.05) The results of the inhibition test showed that Fel d 2 and Can f 3 had high inhibition rates of four epithelial allergens, ranging from 66.5% to 91.8% and 75.8% to 91.9%, respectively. When lipocalin family components were used as inhibitors, the sIgE inhibition rates of these furry animal extracts were almost all lower than 50%.</p><p><strong>Conclusion: </strong>SA is the primary driver of cross-sensitization between cats, dogs, and other furry animals, rather than lipocalins.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"363-375"},"PeriodicalIF":3.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}